[Lieyun Network (WeChat:ilieyun
) Beijing] Reported on September 29
Lieyun.com recently learned that surgical instrument developer “Kingstron Bio” has announced the completion of a new round of equity financing, led by Panlin Capital, with participation from Jundu Investment and Changshu Guofa Venture Capital.
Panlin Capital stated that there is immense potential for import substitution in China’s market for surgical heart valve repair and replacement products. Leveraging superior product quality and cost advantages, domestic companies are poised to replicate the import substitution trajectory seen with coronary stents. Kingstron Bio is one of the most comprehensive enterprises in China’s structural heart disease sector, offering a portfolio that includes annuloplasty rings, bioprosthetic valves, transcatheter aortic valve systems, and biological patches. Its products integrate the strengths of various imported counterparts and have garnered high recognition from top domestic experts. Through the organization and implementation of clinical trials and collaborative research projects, the company has also established an extensive network of cardiac surgery experts. The founder, Mr. Zhong, possesses deep expertise and a broad vision in cardiovascular medical devices and biomaterials. Known for his pragmatic approach and strong business acumen, he is a serial entrepreneur in the cardiovascular medical device field. We highly anticipate Kingstron Bio’s contributions and performance in the heart valve market.
Jundu Investment stated that with the intensifying trend of population aging and the increasing number of patients with cardiovascular diseases, there will be a substantial market demand for valve replacement and repair products. Kingstron Bio has a rich product pipeline layout, covering various valve replacement/repair products such as annuloplasty rings, bioprosthetic valves, transcatheter aortic valve systems, and biological patches. The founder, Mr. Zhong, is a serial entrepreneur in the field of cardiovascular medical devices, with successful entrepreneurial experience spanning the entire process from product research and development, registration approval to production and sales. He has deep expertise in the field of cardiovascular medical devices. We look forward to Kingstron Bio and Mr. Zhong achieving success again in the field of heart valves, providing better valve products for domestic patients.
Changshu Guofa Venture Capital stated that the current domestic market for heart valves is large, with significant potential for import substitution. Leveraging years of industry experience and independent innovative technologies, Kingstron Bio has positioned itself as a leading provider of a comprehensive portfolio of solutions for cardiac valve functional reconstruction in China, with its full product line capable of meeting the substantial domestic demand. The company’s core team possesses extensive experience in market operations management and sales channel development, demonstrating strong capabilities for future industrialization. As a local state-owned enterprise, Changshu Guofa Venture Capital supports high-quality local businesses in Changshu and looks forward to Kingstron Bio gradually becoming a benchmark enterprise in the field of heart valves.
January 2018,Kingstron Bio Completes RMB 125 Million Series B Financing, led by Salubris Pharmaceutical, with Bangsheng Capital participating as a co-investor.
According to information from the Tianyancha app, Kingstron Bio (Changshu) Co., Ltd. was established in April 2012, with Zhong Shengping serving as its legal representative. The company’s founder and chairman, Dr. Zhong Shengping, is an expert under China’s “Thousand Talents Plan.” He has been engaged in the research and development of biomaterials and heart valves since the 1980s, previously held positions at well-known multinational medical device companies in Europe and the United States, and founded Easyscience Technology, where he successfully industrialized third-generation drug-eluting stents.
Kingstron Bio is a research, development, and manufacturing enterprise specializing in medical devices for structural heart disease. Its product portfolio includes surgical bioprosthetic valves, annuloplasty rings, biological patches, and transcatheter heart valves, making it one of the companies with the most comprehensive product lines in this field in China. The company’s annuloplasty rings have been launched and are commercially available; its surgical bioprosthetic valves have been submitted for regulatory registration; and its third-generation transcatheter aortic valve system is poised to commence patient enrollment for clinical trials.
Through independent R&D, Kingstron Bio has developed a series of internationally leading and industry-forefront core technologies, including anti-calcification treatment, dry storage, and leaflet thinning, securing core patents. The company’s core team possesses extensive R&D experience in cardiovascular implantable devices. Kingstron Bio’s third-generation transcatheter aortic valve system features pre-loading and repositionability, with its R&D progress leading domestically. Positioned as a high-end alternative to imported products, the company aims to capture China’s high-end valve market by leveraging its innovative technologies and first-mover advantage.